Record overview
Status and phase
Status: COMPLETED
Phase: PHASE2
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
Condition: Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
NCT03483103
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.